Alnylam Pharmaceuticals Inc. (ALNY)

81.26
NASDAQ : Health Technology
Prev Close 81.26
Day Low/High 0.00 / 0.00
52 Wk Low/High 78.85 / 153.99
Avg Volume 914.20K
Exchange NASDAQ
Shares Outstanding 100.67M
Market Cap 8.05B
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc.

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting...

Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted an Clinical Trial Authorization (CTA) application to the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a...

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that ONPATTRO (patisiran) is now available in Germany.

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular...

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) And Lead Plaintiff Deadline - November 26, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) And Lead Plaintiff Deadline - November 26, 2018

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc.

ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY

ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alnylam...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc.

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting...

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the...

ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm

ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc.

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the...

Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY

Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alnylam Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Sept. 12, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alnylam Pharmaceuticals, Inc. (ALNY)

NEW YORK, Sept. 12, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc.

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO ™ (patisiran) for the treatment of hereditary transthyretin-mediated...

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5,...

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid...

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements (VBA) with leading health insurers for ONPATTRO™ (patisiran) lipid complex...

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference...

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted patisiran, an investigational RNAi therapeutic in development for the...

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2018 and highlighted recent progress in advancing its pipeline.

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion recommending marketing authorization of patisiran for the...

TheStreet Quant Rating: D (Sell)